IDSA continues working to advance domestic and global policies to address antimicrobial resistance (AMR). Key recent activities include:
Wellcome Trust Global Call to Action:
IDSA Treasurer Helen Boucher, MD, FIDSA, served on a panel in Berlin, Germany in October about measuring success in addressing AMR globally, in which she spoke about the role of health care providers. IDSA Clinical Affairs Committee member Javeed Siddiqui, MD, discussed how telemedicine can allow ID specialists to support the implementation of stewardship globally.
Keynote at World AMR Congress:
IDSA then-President William Powderly, MD, FIDSA, joined the president of the American Society for Microbiology at the World AMR Congress in September for a joint keynote in which he highlighted IDSA’s AMR policy and advocacy efforts and the leading role of ID physicians in implementing antimicrobial stewardship.
WHO Global AMR Activities:
IDSA submitted comments to the World Health Organization (WHO) Interagency Coordination Group (IACG) for AMR, including recommending that WHO and IAGG:
- advance economic incentives for new antimicrobial drugs, diagnostics and vaccines;
- promote research that leads to improved use of existing antibiotics;
- secure an expert infectious diseases workforce to address AMR;
- coordinate AMR and TB activities; create a mechanism to facilitate collaboration and sharing of resources and knowledge;
- facilitate multinational research networks; provide nuanced guidance, tools and training on stewardship that are geared towards the constraints and concerns of individual countries; and
- develop global goals with quantifiable targets, specific timelines and benchmarks for progress.
IDSA offered to provide forums for WHO and the IACG to engage with ID clinicians and scientists and share ID expertise with other countries. The Society also offered feedback on indicators that would be feasible and meaningful for assessing progress on AMR.
Advancing Antibiotic Incentives:
IDSA attended the meeting of DRIVE-AB—a consortium spearheaded by the European Union’s Innovative Medicines Initiative to develop proposals for economic incentives to spur the development of urgently needed new antimicrobial drugs. DRIVE-AB’s recommendations are well-aligned with IDSA’s policies, calling for investment in push incentives (e.g., grants and tax credits that provide support during research and development) and pull incentives (i.e., rewards provided after a new antimicrobial drug is brought to market). DRIVE-AB specifically calls for the development of a generous market entry reward for new antimicrobials that target pathogens identified as priorities by WHO. Under such a proposal, companies receiving the reward would also make commitments regarding stewardship and access. IDSA is convening a working group through our Stakeholder Forum on Antimicrobial Resistance (S-FAR) to develop a complementary market entry reward proposal for the US.
S-FAR, PACCARB and Joint Commission:
IDSA held its annual S-FAR meeting this fall, during which the group strategized about advocacy for federal and global AMR funding and new ways to engage patients in AMR policy efforts. The group also met with staff from the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) and received an update from the Joint Commission (JC) about implementation of its stewardship requirement, which took effect earlier this year.
The JC has begun surveying hospitals to review their stewardship programs. According to initial findings, 14 out of 211 hospitals were cited for one or more deficiencies in their antimicrobial stewardship programs, including:
- Antimicrobial stewardship not a leadership priority (1)
- No evidence of a multidisciplinary team approach (3)
- Program/policy did not include all of the Centers for Disease Control and Prevention’s core elements (3)
- Education not provided to staff and/or Licensed Independent Practioner (5)
- Education not provided to patient/family (2)
< Previous Article | Next Article >